Nick Yeo becomes Chief Executive Officer for Veryan Medical .
Veryan Medical (Horsham) UK has today announced that Nick Yeo will become Chief Executive Officer effective 01 January 2020 succeeding Chas Taylor who is stepping down from the role of CEO, which he has held since 2006, to take up new entrepreneurial opportunities. Nick joined Veryan as Chief Operating Officer in 2011 with a wealth of experience in drug, medical device and combination product development and commercialisation. As COO he has had notable successes, not least the achievement of the fastest IDE to PMA approval of a peripheral stent by the US Food and Drug Administration.
Nick’s oversight of the MIMICS clinical programme continues to generate compelling clinical evidence for the BioMimics 3D Vascular Stent and was a key element in the decision by Otsuka Medical Devices (OMD) to acquire Veryan in December 2018. Nick’s appointment will ensure continuity and stability for Veryan’s fast-growing business that now includes multiple product development programs alongside expanding sales of BioMimics 3D.
Chas will remain on the Veryan Medical Board as a Non-Executive Director and will continue to support Veryan’s business as a consultant. Noriko Tojo, President of Otsuka Medical Devices, commented “On behalf of Otsuka Medical Devices and the OMD Board I would like to congratulate Nick on his new role and also thank Chas for his valuable contribution to our business. Together with Veryan’s management team, Chas has been at the core of managing the transition of Veryan to be a member of the Otsuka Group of Companies and in positioning Veryan for a new stage in its development. We welcome Chas in his new role and wish him all the best for his future endeavours as we welcome Nick to the role of Veryan CEO”.